Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC
NCT06067776Phase 1Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tucatinib, KL-140 and osimertinib in non-small cell lung cancer (NSCLC). Primary endpoint: Maximum Tolerated Dose. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06067776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067776.